Przejdź do
H168
R(+)-7-Hydroxy-DPAT hydrobromide
>98%, solid
Synonim(y):
R(+)-2-Dipropylamino-7-hydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide, R(+)-7-Hydroxy(dipropylamino)tetralin hydrobromide
Zaloguj się, aby wyświetlić ceny organizacyjne i kontraktowe.
Informacje o tej pozycji
Wzór empiryczny (zapis Hilla):
C16H25NO · HBr
Numer CAS:
Masa cząsteczkowa:
328.29
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
assay
>98%
form
solid
color
white
solubility
H2O: >100 mg/mL, ethanol: >56 mg/mL
SMILES string
Br.CCCN(CCC)C1CCc2ccc(O)cc2C1
InChI
1S/C16H25NO.BrH/c1-3-9-17(10-4-2)15-7-5-13-6-8-16(18)12-14(13)11-15;/h6,8,12,15,18H,3-5,7,9-11H2,1-2H3;1H
InChI key
ODNDMTWHRYECKX-UHFFFAOYSA-N
Gene Information
human ... DRD3(1814)
Biochem/physiol Actions
Selective D3 dopamine receptor agonist; active enantiomer of (±)-7-hydroxy-DPAT.
Features and Benefits
This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Disclaimer
Photosensitive
Ta strona może zawierać tekst przetłumaczony maszynowo.
Klasa składowania
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Wybierz jedną z najnowszych wersji:
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
R J Baldessarini et al.
European journal of pharmacology, 239(1-3), 269-270 (1993-08-03)
Racemic 7-hydroxy-N,N-dipropylaminotetralin (7-OH-DPAT) shows greater affinity for limbic-selective dopamine D3 receptors than for more ubiquitous dopamine D2 receptors. R(+)-7-OH-DPAT was prepared and evaluated in radioreceptor assays using membranes of fibroblasts expressing the human dopamine D3 receptor as well as rat
Eriko Ikeda et al.
Molecular pharmacology, 83(5), 959-967 (2013-02-23)
The dopamine D3 receptor (DRD3) in the ventral striatum is thought to influence motivation and motor functions. Although the expression of DRD3 in the ventral striatum has been shown to exhibit 24-hour variations, the mechanisms underlying the variation remain obscure.
Megan E Breuer et al.
European journal of pharmacology, 616(1-3), 134-140 (2009-06-25)
Treatment with pramipexole, a dopamine D(3)/D(2) receptor agonist, reduces depressive symptoms in patients suffering from Parkinson's disease. To test the putative antidepressant quality of pramipexole, its effects were assessed in one of the most attractive animal models of depression, the